Evidence map›Paper›PMID 38860206›Full record

ArticleFrontiers in medicine2024

PCSK9 inhibitors ameliorate arterial stiffness in ACS patients: evidences from Mendelian randomization, a retrospective study and basic experiments.

Linghao Xu, Liang Wang, Yuanqi Wang, Yiqiong Wang, Yuanzhen Jiang, Peizhao Du, Jing Cheng, Chunsheng Zhang, Ruijie Wang, Tiantian Jiao and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Linghao Xu *Department of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Liang Wang *Department of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Yuanqi Wang *Department of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Yiqiong WangDepartment of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Yuanzhen JiangShanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai, China.
Peizhao DuDepartment of Cardiology, Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine of Shanghai, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jing ChengDepartment of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Chunsheng ZhangDepartment of Cardiology, East Hospital of Clinical Medical College, Nanjing Medical University, Nanjing, China.
Ruijie WangDepartment of Cardiology, Harbin Medical University First Affiliated Hospital, Harbin, China.
Tiantian JiaoDepartment of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Lijian XingDepartment of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Jiangping MaSchool of Medicine, Tongji University, Shanghai, China.
Jiming LiDepartment of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Current evidences suggest that Proprotein Convertase Subtilisin/kexin Type 9 inhibitors (PCSK9i) exhibit a protective influence on acute coronary syndrome (ACS). Nevertheless, further investigation is required to comprehend the impact and mechanisms of these pharmaceutical agents on inflammatory factors and arterial stiffness (AS) in patients with ACS. Consequently, the objective of this study is to ascertain the influence of PCSK9i on arterial stiffness in ACS patients and elucidate the underlying mechanisms behind their actions. Methods: This study employed Mendelian randomization (MR) analysis to examine the association between genetic prediction of PCSK9 inhibition and arterial stiffness. Data of 71 patients with ACS were retrospectively collected, including PCSK9i group ( Results: The results of the MR analysis suggest that genetic prediction of PCSK9 inhibition has potential to reduce the PWV. Following treatment of statins combined with PCSK9 inhibitors for 1 and 6 months, the PCSK9i group exhibited significantly lower levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), C-reactive protein (CRP), interleukin-6 (IL-6), fibrinogen (FIB) and procalcitonin (PCT) compared to the control group ( Conclusion: PCSK9i have potential to enhance arterial stiffness in ACS patients. Specifically, at the clinical level, this impact may be attributed to alterations in circulating CRP levels. At the cellular level, it is associated with the signaling pathway linked to RUNX2.

Indexed as

acute coronary syndromesarterial stiffnessC-reactive proteinMendelian randomizationPCSK9 inhibitors

Identifiers

PMID38860206
PMCPMC11163136

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.